Sofinnova Partners

Developing next-generation biologics for severe immunological and inflammatory diseases

Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development

Designs and manufactures renewable specialty ingredients for personal care, fragrance, and performance materials

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

Develops NEUROMARK, a minimally invasive solution to treat chronic rhinitis